Covered recipient · General Payments record
VIRGINIA OTEY VILLARREAL
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Family
General Payments · PY2021–2023
$1,028.22
- Reported across 56 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2023 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $266.32 | 15 |
By paying entity
PY2023 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Medtronic, Inc. | $91.09 | 5 |
| Amphastar Pharmaceuticals, Inc. | $27.25 | 1 |
| BETA BIONICS, INC. | $20.97 | 1 |
| Alexion Pharmaceuticals, Inc. | $19.47 | 1 |
| Corcept Therapeutics | $18.77 | 1 |
| Ultragenyx Pharmaceutical Inc. | $18.15 | 1 |
| DEXCOM, INC. | $16.12 | 1 |
| Kyowa Kirin, Inc. | $14.51 | 1 |
| Amgen Inc. | $14.00 | 1 |
| Novo Nordisk AS | $13.19 | 1 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $12.80 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2023 (15)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $19.47 | 07/11/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1017067237 | CMS |
| Amgen Inc. | $14.00 | 03/08/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1020522339 | CMS |
| Amphastar Pharmaceuticals, Inc. | $27.25 | 11/02/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1053556595 | CMS |
| BETA BIONICS, INC. | $20.97 | 11/15/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1060384381 | CMS |
| Corcept Therapeutics | $18.77 | 04/20/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1050814317 | CMS |
| Dexcom, Inc. | $16.12 | 03/15/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1054796814 | CMS |
| Kyowa Kirin, Inc. | $14.51 | 06/21/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1027050469 | CMS |
| Medtronic, Inc. | $23.45 | 02/02/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1025866281 | CMS |
| Medtronic, Inc. | $14.41 | 02/09/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1025866271 | CMS |
| Medtronic, Inc. | $14.75 | 06/06/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1025866289 | CMS |
| Medtronic, Inc. | $19.24 | 06/07/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1025866303 | CMS |
| Medtronic, Inc. | $19.24 | 10/12/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1025866311 | CMS |
| Novartis Pharmaceuticals Corporation | $12.80 | 11/08/2023 | Food and Beverage | Undisputed | 01/23/2026 | 993419637 | CMS |
| Novo Nordisk Inc | $13.19 | 07/19/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1001908975 | CMS |
| Ultragenyx Pharmaceutical Inc. | $18.15 | 06/23/2023 | Food and Beverage | Undisputed | 01/23/2026 | 1059062031 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023
- Source files
- Dataset page · Bulk file · PY2021 , PY2022 , PY2023
- Generated from
- OP_DTL_GNRL_PGYR2023_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.